Abstract:BACKGROUND & AIMS: <AbstractText Label="BACKGROUND & AIMS" NlmCategory="OBJECTIVE">RNA N6-methyladenosine (m6A) reader protein YTHDF1 has been implicated in cancer; however, its role in hepatocellular carcinoma (HCC), especially in non-alcoholic steatohepatitis-associated HCC (NASH-HCC), remains unknown. Here, we investigated the functional role of YTHDF1 in NASH-HCC and its interplay with the tumor immune microenvironment.</AbstractText>METHODS: <AbstractText Label="METHODS" NlmCategory="METHODS">Hepatocyte-specific Ythdf1-overexpressing mice were subjected to a NASH-HCC-inducing diet. Tumor-infiltrating immune cells were profiled with single-cell RNA-sequencing, flow cytometry, and immunostaining. The molecular target of YTHDF1 was elucidated with RNA-sequencing, m6A-sequencing, YTHDF1 RNA immunoprecipitation-sequencing, proteomics, and ribosome-profiling. Ythdf1 in NASH-HCC models was targeted by lipid nanoparticle (LNP)-encapsulated small-interfering Ythdf1.</AbstractText>RESULTS: <AbstractText Label="RESULTS" NlmCategory="RESULTS">YTHDF1 is overexpressed in tumor tissues compared to adjacent peri-tumor tissues from patients with NASH-HCC. Liver-specific Ythdf1 overexpression drives tumorigenesis in dietary models of spontaneous NASH-HCC. Single-cell RNA-sequencing and flow cytometry revealed that Ythdf1 induced accumulation of myeloid-derived suppressor cells (MDSCs) and suppressed cytotoxic CD8+ T-cell function. Mechanistically, Ythdf1 expression in NASH-HCC cells induced the secretion of IL-6, which mediated MDSC recruitment and activation, leading to CD8+ T-cell dysfunction. EZH2 mRNA was identified as a key YTHDF1 target. YTHDF1 binds to m6A-modified EZH2 mRNA and promotes EZH2 translation. EZH2 in turn increased expression and secretion of IL-6. Ythdf1 knockout synergized with anti-PD-1 treatment to suppress tumor growth in NASH-HCC allografts. Furthermore, therapeutic targeting of Ythdf1 using LNP-encapsulated small-interfering RNA significantly increased the efficacy of anti-PD-1 blockade in NASH-HCC allografts.</AbstractText>CONCLUSIONS: <AbstractText Label="CONCLUSIONS" NlmCategory="CONCLUSIONS">We identified that YTHDF1 promotes NASH-HCC tumorigenesis via EZH2-IL-6 signaling, which recruits and activates MDSCs to cause cytotoxic CD8+ T-cell dysfunction. YTHDF1 may be a novel therapeutic target to improve responses to anti-PD-1 immunotherapy in NASH-HCC.</AbstractText>IMPACT AND IMPLICATIONS: <AbstractText Label="IMPACT AND IMPLICATIONS" NlmCategory="UNASSIGNED">YTHDF1, a N6-methyladenosine reader, is upregulated in patients with non-alcoholic steatohepatitis (NASH)-associated hepatocellular carcinoma (HCC); however, its role in modulating the tumor immune microenvironment in NASH-HCC remains unclear. Here, we show that Ythdf1 mediates immunosuppression in NASH-HCC and that targeting YTHDF1 in combination with immune checkpoint blockade elicits robust antitumor immune responses. Our findings suggest novel therapeutic targets for potentiating the efficacy of immune checkpoint blockade in NASH-HCC and provide the rationale for developing YTHDF1 inhibitors for the treatment of NASH-HCC.</AbstractText>

Supplementary Data from Activation of YAP1 by N<sup>6</sup>-Methyladenosine–Modified Circcpsf6 Drives Malignancy in Hepatocellular Carcinoma

Supplementary Data from Activation of YAP1 by N<sup>6</sup>-Methyladenosine–Modified circCPSF6 Drives Malignancy in Hepatocellular Carcinoma

Activation of YAP1 by N6-Methyladenosine-Modified Circcpsf6 Drives Malignancy in Hepatocellular Carcinoma.

Interleukin-6 Induced by YAP in Hepatocellular Carcinoma Cells Recruits Tumor-Associated Macrophages

Hsa_circ_0014784-induced YAP1 promoted the progression of pancreatic cancer by sponging miR-214-3p

SET1A-Mediated Mono-Methylation at K342 Regulates YAP Activation by Blocking Its Nuclear Export and Promotes Tumorigenesis.

M6a Modification of Circhps5 and Hepatocellular Carcinoma Progression Through HMGA2 Expression

CSN6‐SPOP‐HMGCS1 Axis Promotes Hepatocellular Carcinoma Progression via YAP1 Activation

Preliminary study on the cellular and molecular mechanisms of Cms1 ribosomal small subunit homolog promoting hepatocellular carcinoma progression via activation of the homolog family member A/yes-associated protein 1 signaling pathway

N6-methyladenosine reader YTHDF1 promotes stemness and therapeutic resistance in hepatocellular carcinoma by enhancing NOTCH1 expression

YAP is a Critical Oncogene in Human Cholangiocarcinoma

Methyltransferase-Like 3-Mediated m6A Methylation of Hsa_circ_0058493 Accelerates Hepatocellular Carcinoma Progression by Binding to YTH Domain-Containing Protein 1

N6-Methyladenosine-Modified ATP8B1-AS1 Exerts Oncogenic Roles in Hepatocellular Carcinoma Via Epigenetically Activating MYC

Targeting N6-methyladenosine reader YTHDF1 with siRNA boosts anti-tumor immunity in NASH-HCC by inhibiting EZH2-IL-6 axis

Targeting N6-methyladenosine Reader YTHDF1 with Sirna Boosts Antitumor Immunity in NASH-HCC by Inhibiting EZH2-IL-6 Axis.

Identification and Validation of the N6-Methyladenosine RNA Methylation Regulator YTHDF1 as a Novel Prognostic Marker and Potential Target for Hepatocellular Carcinoma

Supplementary Figures S1-S4 from YAP Promotes Malignant Progression of <i>Lkb1</i>-Deficient Lung Adenocarcinoma through Downstream Regulation of Survivin

SIRT1 regulates YAP2-mediated cell proliferation and chemoresistance in hepatocellular carcinoma

HIF-1α-induced expression of m6A reader YTHDF1 drives hypoxia-induced autophagy and malignancy of hepatocellular carcinoma by promoting ATG2A and ATG14 translation

Hypoxia-enhanced YAP1-EIF4A3 interaction drives circ_0007386 circularization by competing with CRIM1 pre-mRNA linear splicing and promotes non-small cell lung cancer progression

Circ_kiaa1429 Accelerates Hepatocellular Carcinoma Advancement Through the Mechanism of M6a-Ythdf3-zeb1

Supplementary Data from Activation of YAP1 by N&lt;sup&gt;6&lt;/sup&gt;-Methyladenosine–Modified Circcpsf6 Drives Malignancy in Hepatocellular Carcinoma